Efficacy of total glucosides of Paeony combined with leflunomide in the treatment of rheumatoid arthritis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076293

Enrollment

Unknown

Registered

2023-09-28

Start date

2023-09-30

Completion date

Unknown

Last updated

2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

control group:Leflunomide

treatment group:Total glucoside of paeony + leflunomide

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) RA was confirmed by MRI, blood routine and other laboratory tests and clinical diagnosis; (2) There are clinical symptoms such as morning stiffness, joint swelling and pain; (3) boneless cancer; (4) Complete medical records; (5) Good compliance, can cooperate with treatment.

Exclusion criteria

Exclusion criteria: (1) Combined with systemic lupus erythematosus; (2) Combined with severe knee osteoarthritis; (3) Combined with serious primary diseases of endocrine system; (4) Allergy to the drug or drug ingredient in the study; (5) Combined with sjogren's syndrome; (6) Use of hormone drugs within the past 1 month; (7) Pregnant or lactating women; (8) Patients with severe consciousness disorder or cognitive impairment were unable to cooperate with the study.

Design outcomes

Primary

Measure	Time frame
Visual analog rating scale;DAS28 score;	—

Secondary

Measure	Time frame
RF;CRP;	—

Countries

Chin

Contacts

Public ContactMaozhen

Caidian District People's Hospital of Wuhan

517994770@qq.com+86 135 5425 9380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026